Annovis Bio, Inc. ANVS
We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ ("APP"), tau/phospho-tau ("tau"), α-Synuclein ("αSYN") and TDP43 — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our completed clinical studies in AD and PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| R&D | $25.2M | $20.0M | $38.8M | $16.5M | $8.5M | $3.1M | $776.3K | — |
| SG&A | $4.5M | $6.7M | $6.2M | $9.0M | $6.1M | $3.6M | $829.4K | — |
| Total operating expenses | $29.7M | $26.7M | $45.0M | $25.5M | $14.5M | $6.6M | $1.6M | — |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M | -$6.6M | -$1.6M | — |
| Pre-tax income | -$28.9M | — | -$56.2M | -$25.3M | -$14.5M | -$5.5M | -$991.0K | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M | -$14.5M | -$5.5M | -$991.0K | — |
| EPS, basic | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 | -0.87 | — | — |
| EPS, diluted | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 | — |
| Shares, diluted (wtd. avg.) | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1.9K | $35.3K |
| Total current assets | — | — | $10.2M | $36.0M | $46.0M | $8.1M | $747.5K | — |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M | $1.1M | — |
| Accounts payable | $2.6M | $2.3M | $1.3M | $4.0M | $688.1K | $341.9K | $1.2M | — |
| Total current liabilities | $3.6M | $3.9M | $4.3M | $7.7M | $1.5M | $578.4K | $2.0M | — |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $1.5M | $578.4K | $2.6M | — |
| Retained earnings | -$163.7M | -$134.8M | -$110.3M | -$54.1M | -$28.7M | -$14.2M | -$8.8M | — |
| Total equity | $16.9M | $9.3M | -$7.8M | $28.3M | $44.5M | $7.5M | -$8.6M | -$7.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$21.9M | -$40.0M | -$17.3M | -$9.1M | -$4.0M | -$476.5K | — |
| Stock-based compensation | $1.8M | $3.8M | $4.6M | $9.2M | $4.7M | $1.9M | $8.5K | — |
| Financing cash flow | $34.6M | $26.7M | $17.3M | $4.6K | $46.7M | $12.0M | $443.1K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-027751.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$991.0K | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |